251 related articles for article (PubMed ID: 34780299)
1. Health insurance coverage and switching among people with hemophilia A in the United States.
He C; Hinds D; Pezalla E; Cheng D; Chen E; Sammon J; Solari PG; Recht M
J Manag Care Spec Pharm; 2022 Feb; 28(2):232-243. PubMed ID: 34780299
[No Abstract] [Full Text] [Related]
2. Health care costs and resource utilization among commercially insured adult patients with hemophilia A managed with FVIII prophylaxis in the United States.
Thornburg CD; Adamski K; Cook K; Vembusubramanian M; Sendhil SR; Hinds D; Chen E; Sammon J; Solari P; Garrison LP; Croteau SE
J Manag Care Spec Pharm; 2022 Apr; 28(4):449-460. PubMed ID: 34958235
[No Abstract] [Full Text] [Related]
3. Health care resource utilization and costs among adult patients with hemophilia A on factor VIII prophylaxis: an administrative claims analysis.
Croteau SE; Cook K; Sheikh L; Chawla A; Sammon J; Solari P; Kim B; Hinds D; Thornburg CD
J Manag Care Spec Pharm; 2021 Mar; 27(3):316-326. PubMed ID: 33645244
[No Abstract] [Full Text] [Related]
4. A Retrospective Observational Study of Rurioctocog Alfa Pegol in Clinical Practice in the United States.
Aledort L; Milligan S; Watt M; Booth J
J Manag Care Spec Pharm; 2020 Apr; 26(4):492-503. PubMed ID: 32223610
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of clinical characteristics, health care resource utilization, and cost outcomes of hemophilia A carriers and noncarriers in the United States: A real-world comparative analysis.
Xing S; Batt K; Kuharic M; Bullano M; Caicedo J; Chakladar S; Markan R; Farahbakhshian S
J Manag Care Spec Pharm; 2023 Jun; 29(6):626-634. PubMed ID: 37276033
[No Abstract] [Full Text] [Related]
6. Understanding the evolution of coverage policies for prophylaxis treatments of hemophilia A without inhibitors: a payer Delphi panel.
Graf M; Tuly R; Harley C; Pednekar P; Batt K
J Manag Care Spec Pharm; 2021 Aug; 27(8):996-1008. PubMed ID: 33843253
[No Abstract] [Full Text] [Related]
7. A Real-World Analysis of Commonly Prescribed FVIII Products Based on U.S. Medical Charts: Consumption and Bleeding Outcomes in Hemophilia A Patients.
Yan S; Maro GS; Desai V; Simpson ML
J Manag Care Spec Pharm; 2020 Oct; 26(10):1258-1265. PubMed ID: 32820685
[TBL] [Abstract][Full Text] [Related]
8. Comparing Factor Use and Bleed Rates in U.S. Hemophilia A Patients Receiving Prophylaxis with 3 Different Long-Acting Recombinant Factor VIII Products.
Simpson ML; Desai V; Maro GS; Yan S
J Manag Care Spec Pharm; 2020 Apr; 26(4):504-512. PubMed ID: 32020842
[TBL] [Abstract][Full Text] [Related]
9. Model of Short- and Long-Term Outcomes of Emicizumab Prophylaxis Treatment for Persons with Hemophilia A.
Zhou ZY; Raimundo K; Patel AM; Han S; Ji Y; Fang H; Zhong J; Betts KA; Mahajerin A
J Manag Care Spec Pharm; 2020 Sep; 26(9):1109-1120. PubMed ID: 32452276
[TBL] [Abstract][Full Text] [Related]
10. Characterizing demographics, comorbidities, and costs of care among populations with Duchenne muscular dystrophy with Medicaid and commercial coverage.
Klimchak AC; Szabo SM; Qian C; Popoff E; Iannaccone S; Gooch KL
J Manag Care Spec Pharm; 2021 Oct; 27(10):1426-1437. PubMed ID: 34595954
[No Abstract] [Full Text] [Related]
11. A regional analysis of payer and provider views on cholesterol management: PCSK9 inhibitors as an illustrative alignment model.
McCormick D; Bhatt DL; Bays HE; Taub PR; Caldwell KA; Guerin CK; Steinhoff J; Ahmad Z; Singh R; Moreo K; Carter J; Heggen CL; Sapir T
J Manag Care Spec Pharm; 2020 Dec; 26(12):1517-1528. PubMed ID: 33251993
[No Abstract] [Full Text] [Related]
12. Health Care Utilization and Economic Burden in Patients with Central Precocious Puberty: An Assessment of the Commercially Insured and Medicaid Populations.
Klein K; Soliman AM; Bonafede M; Nelson JK; Grubb E
J Manag Care Spec Pharm; 2019 Jul; 25(7):836-846. PubMed ID: 31232203
[TBL] [Abstract][Full Text] [Related]
13. Assessment of racial and ethnic inequities in copay card utilization and enrollment in copay adjustment programs.
Ingham M; Sadik K; Zhao X; Song J; Fendrick AM
J Manag Care Spec Pharm; 2023 Sep; 29(9):1084-1092. PubMed ID: 37548953
[No Abstract] [Full Text] [Related]
14. Coverage of Nonpharmacologic Treatments for Low Back Pain Among US Public and Private Insurers.
Heyward J; Jones CM; Compton WM; Lin DH; Losby JL; Murimi IB; Baldwin GT; Ballreich JM; Thomas DA; Bicket MC; Porter L; Tierce JC; Alexander GC
JAMA Netw Open; 2018 Oct; 1(6):e183044. PubMed ID: 30646222
[TBL] [Abstract][Full Text] [Related]
15. The cost impact of disease progression to metastatic castration-sensitive prostate cancer.
Trinh QD; Chaves LP; Feng Q; Zhu J; Sandin R; Abbott T
J Manag Care Spec Pharm; 2022 May; 28(5):544-554. PubMed ID: 35471070
[No Abstract] [Full Text] [Related]
16. Health care resource utilization and costs among individuals with vs without Huntington disease in a US population.
To TM; Exuzides A; Abbass IM; Patel AM; Ta JT; Surinach A; Fuller RLM; Luo J
J Manag Care Spec Pharm; 2022 Nov; 28(11):1228-1239. PubMed ID: 36282937
[No Abstract] [Full Text] [Related]
17. Clinical and economic characterization of mild, moderate, and severe systemic lupus erythematosus: Real-world observation across payer channels in the United States.
Wu SS; Perry A; Tkacz J; Bryant G
J Manag Care Spec Pharm; 2023 Sep; 29(9):1010-1020. PubMed ID: 37610115
[No Abstract] [Full Text] [Related]
18. Health care costs and resource use of managing hemophilia A: A targeted literature review.
Chen Y; Cheng SJ; Thornhill T; Solari P; Sullivan SD
J Manag Care Spec Pharm; 2023 Jun; 29(6):647-658. PubMed ID: 37276036
[No Abstract] [Full Text] [Related]
19. Burden of illness in patients with possible Lennox-Gastaut syndrome: A retrospective claims-based study.
Reaven NL; Funk SE; Montouris GD; Saurer TB; Story TJ
Epilepsy Behav; 2018 Nov; 88():66-73. PubMed ID: 30241056
[TBL] [Abstract][Full Text] [Related]
20. Economic burden of growth hormone deficiency in a US pediatric population.
Kaplowitz P; Manjelievskaia J; Lopez-Gonzalez L; Morrow CD; Pitukcheewanont P; Smith A
J Manag Care Spec Pharm; 2021 Aug; 27(8):1118-1128. PubMed ID: 33896224
[No Abstract] [Full Text] [Related]
[Next] [New Search]
